Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Daiichi Sankyo ADR DSNKY

Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (PINL:DSNKY)

ETNA-AF-Europe Registry Data on LIXIANA®?(edoxaban) Published in a Leading Cardiology Journal Highlights Important Clinical Considerations for Treating Ageing Patients with Atrial Fibrillation

PR Newswire August 20, 2020

Large Real-World Data Confirm Safety and Effectiveness of LIXIANA®? (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities

PR Newswire December 18, 2019

Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA®? (edoxaban) in Patients with Atrial Fibrillation

PR Newswire September 4, 2019

ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA®? (edoxaban) in Elderly NVAF Patients

PR Newswire September 2, 2019

CLEAR Wisdom Demonstrated First-in-class, Oral, Once-daily, ACL Inhibitor Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP

Stockhouse Editorial March 19, 2019

Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA®▼ (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation

Stockhouse Editorial March 18, 2019

Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet

Stockhouse Editorial January 7, 2019

Daiichi Sankyo Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference

PR Newswire November 19, 2018

Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15, 2018

PR Newswire November 8, 2018

Opinion & Analysis (PINL:DSNKY)

No current opinion is available.

Bullboard Posts (PINL:DSNKY)

FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung

BREAKING NEWS: $DSNKY FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug | BenzingaOn Wednesday, the FDA issued a...
whytestocks - June 27, 2024